Roth Affirms Cytokinetics (CYTK) at 'Buy' Following Enrollment of First VIGOR-ALS Patient

October 18, 2016 9:55 AM EDT Send to a Friend
Roth Capital affirms Cytokinetics (Nasdaq: CYTK) at Buy with a price target of $22 after the company announced the first ...

To continue reading this article and more like it please sign-in or join today (FREE!)

Member Login